NICE backs Lynparza across the board for BRCA+ovarian cancer

FDA guidance finally opens door for insulin biosimilars

New draft guidance from the FDA has opened the door for the development of insulin biosimilars, potentially allowing for cheaper near-identical versions of these biologic drugs to be interc

Q&A: Zulf Masters on emerging markets

UK-based Masters Speciality Pharma focuses on supplying medicines to developing countries where access to treatments is limited – partnering with big pharma firms such as Novartis, Alex